🚀 VC round data is live in beta, check it out!
AstraZeneca Pharma India Valuation Multiples
Discover revenue and EBITDA valuation multiples for AstraZeneca Pharma India and similar public comparables like Ocular Therapeutix, BioKangtai, Pfizer India, Dianthus Therapeutics and more.
AstraZeneca Pharma India Overview
About AstraZeneca Pharma India
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
Founded
1979
HQ
Employees
802
Website
Sectors
Financials (FY)
EV
$2B
AstraZeneca Pharma India Financials
AstraZeneca Pharma India reported last fiscal year revenue of $187M and EBITDA of $22M.
In the same fiscal year, AstraZeneca Pharma India generated $78M in gross profit, $22M in EBITDA, and $13M in net income.
Revenue (LTM)
AstraZeneca Pharma India P&L
In the most recent fiscal year, AstraZeneca Pharma India reported revenue of $187M and EBITDA of $22M.
AstraZeneca Pharma India expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $187M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $78M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBITDA | — | XXX | $22M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 13% | XXX | XXX | XXX |
| Net Profit | — | XXX | $13M | XXX | XXX | XXX |
| Net Margin | — | XXX | 7% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AstraZeneca Pharma India Stock Performance
AstraZeneca Pharma India has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
AstraZeneca Pharma India's stock price is $96.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.4% | XXX | XXX | XXX | $0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAstraZeneca Pharma India Valuation Multiples
AstraZeneca Pharma India trades at 12.7x EV/Revenue multiple, and 109.6x EV/EBITDA.
EV / Revenue (LTM)
AstraZeneca Pharma India Financial Valuation Multiples
As of March 7, 2026, AstraZeneca Pharma India has market cap of $2B and EV of $2B.
Equity research analysts estimate AstraZeneca Pharma India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AstraZeneca Pharma India has a P/E ratio of 190.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 12.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 109.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 100.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 30.4x | XXX | XXX | XXX |
| P/E | — | XXX | 190.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 340.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AstraZeneca Pharma India Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AstraZeneca Pharma India Margins & Growth Rates
AstraZeneca Pharma India's revenue in the last fiscal year grew by 7%.
AstraZeneca Pharma India Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (5%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AstraZeneca Pharma India Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ocular Therapeutix | XXX | XXX | XXX | XXX | XXX | XXX |
| BioKangtai | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| Dianthus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Anhui Anke Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AstraZeneca Pharma India M&A Activity
AstraZeneca Pharma India acquired XXX companies to date.
Last acquisition by AstraZeneca Pharma India was on XXXXXXXX, XXXXX. AstraZeneca Pharma India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AstraZeneca Pharma India
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAstraZeneca Pharma India Investment Activity
AstraZeneca Pharma India invested in XXX companies to date.
AstraZeneca Pharma India made its latest investment on XXXXXXXX, XXXXX. AstraZeneca Pharma India invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AstraZeneca Pharma India
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AstraZeneca Pharma India
| When was AstraZeneca Pharma India founded? | AstraZeneca Pharma India was founded in 1979. |
| Where is AstraZeneca Pharma India headquartered? | AstraZeneca Pharma India is headquartered in India. |
| How many employees does AstraZeneca Pharma India have? | As of today, AstraZeneca Pharma India has over 802 employees. |
| Is AstraZeneca Pharma India publicly listed? | Yes, AstraZeneca Pharma India is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of AstraZeneca Pharma India? | AstraZeneca Pharma India trades under ASTRAZEN ticker. |
| When did AstraZeneca Pharma India go public? | AstraZeneca Pharma India went public in 2001. |
| Who are competitors of AstraZeneca Pharma India? | AstraZeneca Pharma India main competitors are Ocular Therapeutix, BioKangtai, Pfizer India, Dianthus Therapeutics. |
| What is the current market cap of AstraZeneca Pharma India? | AstraZeneca Pharma India's current market cap is $2B. |
| What is the current revenue of AstraZeneca Pharma India? | AstraZeneca Pharma India's last fiscal year revenue is $187M. |
| What is the current EV/Revenue multiple of AstraZeneca Pharma India? | Current revenue multiple of AstraZeneca Pharma India is 12.7x. |
| Is AstraZeneca Pharma India profitable? | No, AstraZeneca Pharma India is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.